Drug Trial Radar · NCT04055909
Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock
Last checked: Nov 19, 2026Latest source record: Apr 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
355
Actual
Start
Nov 13, 2019
Primary completion
May 9, 2022
Study completion May 9, 2023
Sponsor
- Lead sponsor
- InotremIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled dose-selection study in which two doses of nangibotide are tested versus placebo.
Conditions
- Shock, Septic
Interventions
nangibotide low doseDrug
nangibotide 0.3 mg/kg/h
nangibotide high doseDrug
nangibotide 1.0 mg/kg/h
placeboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sequential organ failure assessment (SOFA) scoreTime frame: day 5
Locations
43 sites in 6 countries. Site status is shown where the registry gives one.
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Ziekenhuis Oost-Limburg
Genk, Belgium
UZ Gent
Ghent, Belgium
Centre hospitalier Jolimont-Lobbes
La Louvière, Belgium
CHU Marie Curie
Lodelinsart, Belgium
Clinique Saint-Pierre
Ottignies, Belgium
CHU UCL Namur asbl
Yvoir, Belgium
Nordsjællandshospital Hillerød
Hillerød, Denmark
Helsinki University Hospital Adult ICU PPDS
Helsinki, Finland
Kuopion Yliopistollinen sairaala
Kuopio, Finland
Tampereen yliopistollinen sairaala
Tampere, Finland
CHU Angers
Angers, France
Centre hospitalier Victor Dupouy
Argenteuil, France
Centre hospitalier de Béthune
Béthune, France
Hôpital Fleyriat
Bourg-en-Bresse, France
CHU Dijon - Hôpital François Mitterrand
Dijon, France
CHD les Oudairies
La Roche-sur-Yon, France
Hôpital de Bicêtre
Le Kremlin-Bicêtre, France
CHU LE Mans
Le Mans, France
CHRU Lille - Hôpital Roger Salengro
Lille, France
Hôpital Universitaire Dupuytren
Limoges, France
Centre Hospitalier Lyon Sud
Lyon, France
Hôpital Nord
Marseille, France
Centre hospitalier de Melun
Melun, France
CHRU Nancy - Hôpital Central
Nancy, France
Hôtel Dieu - Nanates
Nantes, France
CHU de Nîmes
Nîmes, France
Hôpital de la source
Orléans, France
Hôpital Lariboisière
Paris, France
Hôpital Saint Louis
Paris, France
Groupe hospitalier Pitié-Salpêtrière
Paris, France
Hôpital Cochin
Paris, France
CHRU Hôpital Bretonneau
Tours, France
Hôpital d'instruction des Armées Robert Picqué
Villenave-d'Ornon, France
St Jame's Hospital
Dublin, Ireland
Galway University Hospital
Galway, Ireland
Hospital del mar
Barcelona, Spain
Hospital Universitario Vall d'Hebrón
Barcelona, Spain
Hospital Clinical San Carlos
Madrid, Spain
Hospital Universitario Dentral de Asturias
Oviedo, Spain
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.